FULC Latest Headlines

Fulcrum Extends Pociredir Program With Long-Term Sickle Cell Study

at www.tipranks.com (Fri, 20-Mar 12:32 PM)

Analysts Offer Insights on Healthcare Companies: Taysha Gene Therapies (TSHA) and Fulcrum Therapeutics (FULC)

at www.tipranks.com (Fri, 20-Mar 8:51 AM)

Fulcrum Therapeutics Grants 34,000 Stock Options to New Hire—What This Signals About Company Growth

Market Chameleon (Mon, 9-Mar 9:13 AM)

Fulcrum’s Positive 20 mg Pociredir Data Positions Company for Registration Trial and Extends Cash Runway into 2029

Market Chameleon (Tue, 24-Feb 7:31 AM)

Fulcrum Therapeutics Awards 70,000-Share Inducement Option at $10.72: What Does This Mean for Investors?

Market Chameleon (Mon, 9-Feb 7:11 AM)